Rhythm Pharmaceuticals, Inc.
As of Oct 22, 2026, Rhythm Pharmaceuticals is in Stage 3, the topping phase, now in week 5 (since Sep 22, 2026). It closed at $90.90, 22.7% below its 52-week high and below its 200-day average, which is falling.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RYTM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RYTM among Biotechnology231st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …231 | RYTM | Stage 3 · wk 5 | 43 | −7.5% |
Rhythm Pharmaceuticals: quick answers
What stage is Rhythm Pharmaceuticals in?
As of Oct 22, 2026, Rhythm Pharmaceuticals (RYTM) is in Stage 3, the topping phase. It entered Stage 3 on Sep 22, 2026 and is in week 5. What the four stages mean
Is Rhythm Pharmaceuticals in an uptrend?
Its uptrend has stalled. Rhythm Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 6.8% below its 200-day average, which is falling.
How far is Rhythm Pharmaceuticals from its 52-week high?
Rhythm Pharmaceuticals closed at $90.90 on Oct 22, 2026, 22.7% below its 52-week high of $117.62. Its 52-week low is $75.82.
How has Rhythm Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Rhythm Pharmaceuticals is down 15.2% over the past year and down 13.4% so far in 2026.
Which sector and industry is Rhythm Pharmaceuticals in?
Rhythm Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.